Clinical Experience of the 121 Patients with Testis Tumors.
- Author:
Soo Bang RYU
1
;
Joon Hwa NOH
;
Dong Deuk KWON
;
Bong Ryul OH
;
Kwang Sung PARK
;
Yang Il PARK
;
Young Kyung PARK
;
Moon Kee CHUNG
;
Yoon Kyu PARK
;
Chong Koo SUL
Author Information
1. Department of Urology, Chonnam University, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Testis tumor;
Clinical characteristic;
Chemotherapy
- MeSH:
Drug Therapy;
Follow-Up Studies;
Germ Cells;
Humans;
Lymph Node Excision;
Lymphoma;
Orchiectomy;
Retrospective Studies;
Testis*
- From:Korean Journal of Urology
1999;40(11):1465-1470
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: A multicenter study was performed to evaluate the clinical characteristics and the results of chemotherapy in patients with testicular tumor. MATERIALS AND METHODS: We retrospectively reviewed the records of 121 patients with testicular tumor treated at five university hospital between 1980 and 1997. We analyzed the clinical characteristics, additional treatments after orchiectomy and results of chemotherapy. RESULTS: Patients age ranged from 1 month to 74 years with a mean of 24 years. The common presenting symptoms were scrotal swelling in 63 patients, palpable mass in 50, and testicular pain in 12. The location of the tumor was on the right side in 62, left in 58, and both in 1 with lymphoma. The histologic type was germinal neoplasm in 101 patients, nongerminal neoplasm in 1, and other tumors in 19. Clinically, 76 patients(62.8%) were stage I, 16(13.2%) stage IIa, 12(9.9%) stage IIb, 3(2.5%) stage IIc, 9(7.4%) stage III and 5(4.1%) stage IV. After orchiectomy, 73 patients(60.3%) were underwent close observation, 30(24.8%) chemotherapy, 14(11.6%) radiation therapy, 3(2.5%) radiation plus chemotherapy and 1(0.8%) retroperitoneal lymph node dissection. Among the 33 chemotherapy patients, 12(36.4%) patients achieved a clinical complete remission(CR), 5(15.2%) partial remission(PR), 4(12.1%) minor response and stabilization, 5(15.2%) progression and 7(21.2%) patients were follow-up loss, and the overall clinical response rate was 65.4%. Among the 18 chemotherapy patients with nonseminomatous germ cell tumor(NSGCT), 9(50.0%) patients achieved a clinical CR, 4(22.2%) PR, 1(5.6%) minor response and stabilization, 2(11.1%) progression and 2(11.1%) patients were follow-up loss, and the overall clinical response rate was 81.3%. CONCLUSIONS: Our study group was relatively small and insufficient to evaluate the chemotherapeutic results, but NSGCT seems to have a better clinical response to chemotherapy.
